Investor Relations
Vivos Therapeutics, Inc. NASDAQ: VVOS
Vivos Therapeutics, Inc.
Annual Shareholder Meeting
August 25, 2022
Download Vivos Therapeutics, Inc.
2021 Annual Report
An Important Breakthrough in the Treatment for Mild-to-Moderate Obstructive Sleep Apnea
Vivos offers a multidisciplinary treatment protocol that uses nonsurgical, noninvasive, and cost-effective oral appliance technology prescribed by trained dentists and medical professionals to treat dentofacial abnormalities and/or mild-to-moderate OSA. This revolutionary treatment is called The Vivos Method.
Latest Stock Information
Listen to Kirk Huntsman and Brad Amman at the
34th Annual Roth Conference
Investor Presentation
Download the Vivos Investor Presentation
Fast Company Selects Vivos Therapeutics for 2022
“World’s Most Innovative Companies” List
Media
Corporate Leadership
Our leadership team is devoted to a singular mission: to rid the world of sleep apnea.
News
Vivos Therapeutics Provides Update on Second Quarter Earnings Delay
Delay Due to Technical Revenue Recognition Analysis and Unrelated to Overall Business Health LITTLETON Colorado, August 22, 2022 16:05 ET |...
Vivos Therapeutics to Reschedule Second Quarter 2022 Financial Results Conference Call
August 15, 2022 07:30 ET | Source: Vivos Therapeutics, Inc LITTLETON Colorado, Aug. 15, 2022 Vivos Therapeutics, Inc. (“Vivos” or the “Company'')...
Vivos Therapeutics Schedules Second Quarter 2022 Financial Results Conference Call
Call Scheduled for Monday, August 15, 2022 at 5:00 pm ET LITTLETON Colorado, Aug. 09, 2022 Vivos Therapeutics, Inc. (“Vivos” or the “Company'')...